Opinion|Videos|July 8, 2024
Evolving Best Practices for ESR1 Testing
The breast cancer experts share their clinical experiences and strategies regarding the optimal timing for testing ESR1 mutations in patients with HR+/HER2- metastatic breast cancer, elaborating on how the specific points in the treatment journey at which they recommend testing influence their subsequent treatment decisions and overall approach to patient management.
Advertisement
Episodes in this series
- In your clinical practice, at what specific points in the treatment journey would you recommend testing for ESR1 mutations, and how does the timing of testing impact your subsequent treatment decisions and approach?
- What are your institution’s protocols and best practices regarding the timing and frequency of ESR1 mutations testing throughout the treatment journey
- Can you elaborate further on what an ESR1 mutation is?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5